Remove Branding Remove Marketing Remove Production
article thumbnail

Why Biosimilars Struggle Despite FDA Approval

World of DTC Marketing

Yet, despite FDA approval and being clinically equivalent to their branded counterparts, biosimilars have not lived up to the promise of becoming blockbuster disrupters. The Power of Entrenched Brand Loyalty Biologic manufacturers have spent years, sometimes decades, building trust with physicians and patients. The question is: why?

article thumbnail

When a New Drug Fails at Launch: Who’s Most to Blame?

World of DTC Marketing

Bringing a new drug to market is a high-stakes game. The Brand Team: Missed the Market Reality At the center of many failed launches is a brand team that built a strategy on assumptions rather than evidence. Additionally, the brand team should consider the age of their target audience.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Medical Affairs Is NOT a Tool of Marketing or Sales — It Must Remain Independent

World of DTC Marketing

Medical Affairs is not, and must never be, a servant to Marketing or Sales. Medical Affairs exists to serve science and patients, not brand performance. They are stewards of scientific integrity, not pitchmen for a product. Marketers: Medical is not there to get in your way — they’re there to keep you honest. Document it.

article thumbnail

Pharma DTC Must Evolve in an Era of Rising Mistrust

World of DTC Marketing

For pharma marketers, especially those running direct-to-consumer (DTC) campaigns, this growing mistrust presents a critical moment of reckoning. And that means DTC marketing must evolve. What Needs to Change in DTC Marketing? Let the patient be the protagonist, not the product. Trust can no longer be assumed.

article thumbnail

Pharma’s “Me-Too” Problem: Why Developing Drugs Without Superior Clinical Benefits is a Waste of Money

World of DTC Marketing

Me-too drugs are therapeutics structurally similar or identical in mechanism to existing drugs already approved and marketed. Pharma executives may rationalize these products as a safer bet. After all, the pathway is clearer, clinical trials are predictable, and the market is somewhat guaranteed.

article thumbnail

As More Health Seekers Turn to AI for Answers, Pharma Is Being Left Behind

World of DTC Marketing

However, AI rarely directs users to pharmaceutical brand websites or even approved prescribing information. That means treatment benefits, risks, and brand-specific differentiators may not be represented at all, or worse, may be misrepresented by third parties or outdated data. Why Pharma Is Being Left Out 1. It’s time to change that.

article thumbnail

Addressing Generic Drug Market Challenges: Strategies for Stability and Affordability

Drug Patent Watch

The generic drug market in the United States faces significant challenges, including price volatility, supply chain disruptions, and strategies employed by brand-name manufacturers to delay market entry. To address these issues, several market-based proposals and regulatory reforms have been suggested.